Fundz

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

PUBLIC · HUMAApr 22, 2026

Position

Chief Commercial Officer

Company

Humacyte

Jim Mercadante
DurhamBiotechnologyHealth CareMedical Device

Description

Humacyte has announced the appointment of Jim Mercadante as Chief Commercial Officer. With over 25 years of experience in healthcare and medical technology, he will lead the company's commercial strategy and product expansion.

Quick answer

Humacyte Appoints Jim Mercadante as Chief Commercial Officer (April 22, 2026). Humacyte is based in Durham, North Carolina, United States.

Who is the new Chief Commercial Officer at Humacyte?
Humacyte named Jim Mercadante Chief Commercial Officer, announced April 22, 2026.
What did Humacyte announce on April 22, 2026?
Humacyte has announced the appointment of Jim Mercadante as Chief Commercial Officer. With over 25 years of experience in healthcare and medical technology, he will lead the company's commercial strategy and product expansion.
What does Humacyte do?
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the...
Where is Humacyte based?
Humacyte is based in Durham, North Carolina, United States.
Which similar companies made leadership changes around the same time?
Lumexa Imaging (April 20, 2026), Zimmer (April 28, 2026), Olympus (April 16, 2026) and SCIRENT (April 16, 2026) also announced leadership changes within 45 days of Humacyte.

Source: Fundz verified event record.

Other recent leadership changes in Medical Device and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Humacyte, and when

A new leader at Humacyte brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Humacyte raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Humacyte, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Humacyte. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Humacyte

Location

Durham, North Carolina, United States

About

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Humacyte changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Laura E.
Likely contact at this company
••••••••@••••••••

See Laura E.'s verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Humacyte's next move

Learn about Strategic plan

Humacyte changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.